Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns positive

Q1 FY2026 other income / expenses was $324K, compared with -$725K a year earlier. Trailing-twelve-month other income / expenses was -$1.59M.

Context

  • Other income / expenses amounted to 161.7% of revenue in FY2025, down 2104.5 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near $324K or moves back toward the trailing-twelve-month quarterly average of -$397.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$324K+160.1% QoQ
Last fiscal yearDec 2025
-$2.64M-111.3% YoY
LTMMar 2026
-$1.59M+51.0% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+144.7%——
1 year-111.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(2.64M) USD
Year-over-year change
-111.3%

Other Income / Expenses vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +51.0% is the 4th highest of 9, against a peer median of -28.0%.
  • Other income / expenses amounts to 50.2% of revenue for RANI, versus a peer median of 152.4%.
RANI Competitors
Other Income / Expenses for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$5.31M USD-38.1%——
IPHAInnate Pharma S.A.FY2025€4.25M EUR+101.9%—152.4%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$3.8M USD+106.4%-3.5%21.6%
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.67M USD-17.9%+37.4%507.8%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$1.59M USD+51.0%—50.2%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$2.61M USD+55.1%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$3.08M USD-1482.5%—172.8%
MOLNMolecular Partners AGLTM Mar 2026-CHF 6.37M CHF-427.8%——
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$13.7M USD-653.1%—39.6%
Peer median (excluding RANI) —-28.0%+16.9%152.4%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M001.03M1.63M
Cost of Revenue00822K0900K
Gross Profit2.72M0(822K)1.03M733K
Gross Margin100.0%——100.0%44.9%
Research & Development26.48M36.61M39.62M26.68M20.21M
Selling, General & Admin27.83M26.84M26.48M23.95M19.74M
Operating Expenses54.32M63.45M65.28M54.34M39.04M
Depreciation & Amortization497K548K822K1.03M900K
EBITDA(52.08M)(61.66M)(61.98M)(50.52M)(37.16M)
EBITDA Margin-1917.0%——-4914.7%-2275.5%
Operating Income(51.6M)(63.45M)(66.1M)(53.31M)(38.31M)
Operating Margin-1899.1%——-5186.2%-2346.0%
Interest Income89K1.25M3.3M1.76M827K
Interest Expense466K1.07M5.09M5.03M2.89M
Other Income / Expenses(1.45M)177K(1.78M)23.3M(2.64M)
Income Before Tax(53.05M)(63.27M)(67.88M)(30.02M)(40.95M)
Pre-Tax Margin-1952.4%——-2920.0%-2507.7%
Income Tax Expense41K70K026.57M0
Net Income(8.33M)(30.59M)(33.97M)(30.02M)(29.67M)
Net Margin-306.6%——-2920.0%-1817.1%
EPS (Basic)(0.42)(1.28)(1.33)(1.05)(0.45)
EPS (Diluted)(0.42)(1.28)(1.33)(1.05)(0.45)
Weighted Avg Shares19.53M23.82M25.51M28.48M66.14M
Weighted Avg Shares (Diluted)19.53M23.82M25.51M28.48M66.14M

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.